Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154692 | 1.00 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1BALDH1A1KDM4E | |
| SCHEMBL2178071 | 0.90 | L3MBTL1 (0.53) | L3MBTL1MTNR1AMTNR1BALDH1A1KDM4E | |
| SCHEMBL30786879 | 0.87 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2178238 | 0.87 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2176161 | 0.87 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2322439 | 0.87 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2176160 | 0.87 | L3MBTL1 (0.50) | L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL2180203 | 0.86 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1BAOC3MEN1 | |
| SCHEMBL15474100 | 0.86 | L3MBTL1 (0.56) | L3MBTL1MTNR1AMTNR1BALDH1A1AOC3 | |
| SCHEMBL2180325 | 0.86 | L3MBTL1 (0.49) | L3MBTL1MTNR1AMTNR1BAOC3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519100-B1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | MAPI PHARMA LTD (IL) | 2017-03-15 | — | — | EP | disclosed |
| US-8410176-B2 | Intermediate compounds and processes for the preparation of tapentadol and related compounds | MAPI PHARMA LTD. (IL) | 2013-04-02 | — | — | US | disclosed |
| US-20120283463-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | MAPI PHARMA LIMITED (IL) | 2012-11-08 | — | — | US | disclosed |
| EP-2519100-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | Mapi Pharma Limited (IL) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011092719-A2 | PROCESS FOR THE PREPARATION OF L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES | IND-SWIFT LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011080736-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | MAPI PHARMA HK LIMITED (CN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283463-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | PNMT, OPRK1, CYP2E1 | L3MBTL1 4570/4885MTNR1A 57/4885MTNR1B 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.